Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model

Cancer Letters

Volumn 259, Issue 2, 2008, Pages 240-250

  Xu, Jinshu ^a,b   Zhu, Zheng ^b   Wu, Jie ^b   Liu, Wentao ^b   Shen, Xiangchun ^b   Zhang, Yin ^b   Hu, Zhuoyi ^b   Zhu, Dongya ^a   Roque, Rouel S ^c   Liu, Jingjing ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Gonadotropin releasing hormone; Heat shock protein 65; Immunotherapy; Prostate cancer; Tumor tissue

Indexed keywords

GAMMA INTERFERON; GONADORELIN; HEAT SHOCK PROTEIN 65; IMMUNOLOGICAL ADJUVANT; LUTEINIZING HORMONE; RECOMBINANT VACCINE; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

ANIMALS; ANTIBODY FORMATION; BACTERIAL PROTEINS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CHAPERONINS; GONADOTROPIN-RELEASING HORMONE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON TYPE II; LUTEINIZING HORMONE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TESTOSTERONE; TIME FACTORS; VACCINES, CONJUGATE; VACCINES, SYNTHETIC; VIRAL PROTEINS;

MUS;

EID: 37048999944     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.011     Document Type: Article

References (39)

1. Conn P.M., and Crowley J.W.F. Gonadotropin-releasing hormone and its analogues. New Engl. J. Med. 324 (1991) 93-103
2. Shupnik M.A. Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Bio. Reprod. 54 (1996) 279-286
3. Clayton R.N. Gonadotropin releasing hormone:its action and receptors (review). J. Endocrinol. 120 (1989) 11-19
4. Imai A., Ohno T., Iida K., Fuseya T., Furui T., and Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometral carcinoma and endometrium. Gynecol. Oncol. 55 (1994) 144-148
5. Chatzaki E., Bax C.M.R., Eidne K.A., Anderson L., Grudzinskas J.G., and Gallagher C.J. The expression of gonadotropin-releasing hormone and its receptor in endometral cancer and its relevance as an autocrine growth factor. Cancer Res. 56 (1996) 2055-2065
6. Yin H., Cheng K.W., Hwa H.L., Peng C., Auersperg N., and Leung P.C. Expression of the mRNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci. 62 (1998) 2015-2023
7. Patterson S.G., Balducci L., and Pow-Sang J.M. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 9 (2002) 315-325
8. Kraus S., Naor Z., and Seger R. Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch. Med. Res. 32 (2001) 499-509
9. Hsu C.T., Ting C.Y., Ting C.J., Chen T.Y., Lin C.P., Whang-Peng J., and Hwang J. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res. 60 (2000) 3701-3705
10. Ferro V.A., Khan M.A., Earl E.R., Harvey M.J., Colston A., and Stimson W.H. Influence of carrier protein conjugation site and terminal modification of a GnRH-I peptide sequence in the development of a highly specific anti-fertility vaccine, Part I. Am. J. Reprod. Immunol. 48 (2002) 361-371
11. Meloen R.H. Basic aspects of immunomodulation through active immunisation. Livestock Production Science 42 (1995) 135-145
12. Ferro V.A., and Stimpson W.H. Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer. Eur. J. Cancer 33 (1997) 1468-1478
13. Jacobs E., Watson S.A., Michaeli D., Ellis I.O., and Robertson J.F.R. Anti-gonadotrophin releasing hormone antbodies inhibit the growth of MCF7 human breast cancer xenografts. Brit. J. Cancer 80 (1999) 352-359
14. Robertson I.S., Fraser H.M., Innes G.M., and Jones A.S. Effect of immunological castration on sexual and production characteristics in male cattle. Vet. Rec. 111 (1982) 529-531
15. Grizzle T.B., Esbenshade K.L., and Johnson B.H. Active immunization of boars against gonadotropin releasing hormone. I. Effects on reproductive parameters. Theriogenology 27 (1986) 571-580
16. Amanatullah D.F., Reutens A.T., Zafonte B.T., Fu M., Mani S., and Pestell R.G. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front. Biosci. 5 (2000) 372-390
17. Giri D.K., Chaudhuri M., Jayashankar R., Neelaram G.S., Jayaraman S., and Talwar G.P. Histopathological changes in reproductive organs of male Wistar rats following active immunization against LHRH. Exp. Mol. Pathol. 52 (1990) 54-62
18. Giri D.K., Jayaraman S., Neelaram G.S., Jayashankar R., and Talwar G.P. Prostatic hypoplasia in bonnet monkeys following active immunization with semisynthetic anti-LHRH vaccines. Exp. Mol. Pathol. 54 (1991) 255-264
19. Xu J., Liu J., Duan P., Zhu Z., Ding M., Wu J., Cao R., Hu Z., and Roque R.S. A synthetic gonadotropin-releasing hormone (GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant. Vaccine 23 (2005) 4834-4843
20. Barrios C., Lussow A.R., Van Embden J., Van der Zee R., Rappuoli R., Costantino P., Louis J.A., Lambert P.-H., and Del Giudice G. Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming. Eur. J. Immunol. 22 (1993) 1365-1372
21. Perraut R., Lussow A.R., Gaville S., Garraud O., Matile H., Tougne C., Van Embden J., Van Der Zee R., Lambert P.-H., Gysin J., and Del Giudice G. Successful primate immunization with peptides conjugated to purified protein drivate or mycobacterial heat shock proteins in the absence of adjuvants. Clin. Exp. Immunol. 93 (1993) 382-386
22. Manjili M.H., Henderson R., Wang X.-Y., Chen X., Li Y., Repasky E., Kazim L., and Subjeck J.R. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62 (2002) 1737-1742
23. Bounous D.I., Campagnoli R.P., and Brown J. Comparison of MTT colorimetric assay and tritiated thymidine uptake for lymphocyte proliferation assays using chicken splenocytes. Avian Dis. 36 (1992) 1022-1027
24. Yahalom D., Rahimipour S., Koch Y., Ben-Aroya M., and Fridkin M. Design and synthetic of potent hexapeptide and heptapeptide gonadotropin-releasing hormone antagonists by truncation of a decapeptide analog sequence. J. Med. Chem. 43 (2000) 2831-2836
25. Rahimipour S., Ben-Aroya N., and Koch Y. Design, synthesis and evaluation of a long-acting potent analogue of gonadotropin-releasing hormone. J. Med. Chem. 44 (2001) 3645-3652
26. Carelli C., Audibert F., Gaillard J., and Chedid L. Immunological castration of male mice by a totally synthetic vaccine administered in saline. Proc. Natl. Acad. Sci. USA 79 (1982) 5392-5395
27. Fromme B., Eftekhari P., van Regenmortel M., Hoebeke J., Katz A., and Millar R. A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology 7 (2003) 3262-3269
28. Ferro V.A., and Stimson W.H. Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine 16 (1998) 1095-1103
29. Chu N.R., Wu B., Bantroch S., Wu T.C., Boux L., Siegel M., and Mizzen L. Immunotherapy o human papillmavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121 (2000) 122-216
30. I. Frazer, E6, E7 and VLP based papillomavirus vaccines for prevention of cervical caner. Development of therapeutic cancer vaccines conference held in Los Angeles, April 27-29, 2003.
31. TM fusion: a therpeutic vaccine platform utilizing heat shock protein (HSP) to treat chronic viral infections, development of therapeutic cancer vaccines conference held in Los Angeles, April 27-29, 2003.
32. Ferro V.A. Current advances in antifertility vaccines for fertility control and noncontraceptive applications. Exp. Rev. Vaccines 1 (2002) 443-452
33. Turkstra J.A., Zeng X.Y., van Diepen T.M., Jongbloed A.W., Oonk H.B., van de Wiel D.F.M., and Meloen R.H. Performance of male pigs immunized against GnRH is related to the time of onset of biological response. J. Anim. Sci. 80 (2002) 2953-2959
34. Talwar G.P., Raina K., Gupta J.C., Ray R., Wadhwa S., and Ali M.M. A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy. Vaccine 22 (2004) 3713-3721
35. Lussow A.R., Barrios C., van Embden J., van der Zee R., Verdini A.S., Pessi A., Louis J.A., Lambert P.H., and del Giudice G. Mycobacterial heat-shock proteins as carrier molecules. Eur. J. Immunol. 21 (1991) 2297-2302
36. Ghosh S., and Jackson D.C. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int. Immunol. 11 (1999) 1103-1110
37. Skinner M.A., Prestidge R., Yuan S., Strabala T.J., and Tan P.L. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodaton heat-shock protein. Immunol. 102 (2001) 225-233
38. Ruberti M., de Melo Lima K., dos Santos S.A., Brandao I.T., Soares E.G., Silva C.L., and Rodrigues Júnior J.M. Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J. Drug. Targeting 12 (2004) 195-203
39. Marth T., Strober W., and Kelsall B.L. High dose oral tolerance in ovalbumin TcR-transgenic mice: systemic neutralization of interleukin-12 augments TGF-β secretion and T cell apoptosis. J. Immunol. 157 (1996) 2348-2357